Citius Pharma Posts $5.6M LYMPHIR Sales, Secures $36.5M Financing
Citius Pharma posted $5.6M net revenue in first half fiscal 2026 at 80% gross margin, with payer coverage covering nearly 100% of commercial lives and 83% of target accounts on formulary or in review. After quarter end, Citius Oncology secured $36.5M in debt and equity plus a $5M direct offering.
1. Commercial Launch Progress
In the first half of fiscal 2026, Citius Oncology generated $5.6 million in net revenue from LYMPHIR sales with approximately 80% gross margins. The company advanced 83% of target accounts to formulary inclusion or active review and secured payer coverage for nearly 100% of covered commercial lives.
2. Financing Secured
Subsequent to quarter end, Citius Oncology closed up to $36.5 million in combined debt and equity financing, including an $11.5 million warrant exercise and a $10 million tranche under a senior secured credit facility. Citius Pharma also completed a $5 million registered direct offering to fund field force buildout.
3. European Shipment and Clinical Updates
Initial LYMPHIR shipments began on April 29, 2026 to 19 European, Middle Eastern and Southern European markets via Named Patient Programs. Preliminary topline Phase 1 data showed positive safety and efficacy results for LYMPHIR in combination with pembrolizumab and prior to CAR-T therapy, reinforcing its potential in combination regimens.
4. Financial Position and Outlook
As of March 31, 2026, Citius Pharma held $4.6 million in cash and equivalents, with an expected operational runway through November 2026. The company is continuing FDA engagement on Mino-Lok and Halo-Lido while preparing for the completion of its LYMPHIR commercial field force by mid-summer.